Differential biomarker profiles between unprovoked venous thromboembolism and cancer.
V Sánchez-LópezL GaoM Ferrer-GalvánElena Arellano-OrdenTeresa ElíasLuis Jara PalomaresM I Asensio-CruzM J Castro-PérezF J Rodríguez-MartorellJ L Lobo-BeristainA Ballaz-QuincocesJosé Luis López-CamposV Vila-LianteR Otero-CandeleraPublished in: Annals of medicine (2020)
Levels of TF-positive EVs, D-dimer and sP-selectin are able to discriminate between unprovoked VTD patients not related to cancer and cancer patients not associated with VTD. These results could lead to the application of EVs as biomarkers of both diseases. Key messages: Circulating EVs, specifically TF-positive EVs, in combination with plasmatic markers of hypercoagulable states, such as D-dimer, sP-selectin and antigen TF, are able to discriminate between cancer patients without thrombosis and patients with unprovoked VTD. Research fields could be opened. Future studies will assess if these biomarkers together serve as predicting thrombotic events in cancer populations.